Cargando…
Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma
Melanoma is widely treated with programmed cell death‐1 (PD‐1) inhibitors. As part of their anti‐tumor immunity effect, they increase the susceptibility to cutaneous immune‐related adverse events (cIRAE) among other autoimmune effects. To characterize the manifestations of cIRAE in melanoma patients...
Autores principales: | Shreberk‐Hassidim, Rony, Aizenbud, Lilach, Lussheimer, Shalev, Thomaidou, Elena, Bdolah‐Abram, Tali, Merims, Sharon, Popovtzer, Aron, Maly, Alex, Lotem, Michal, Zlotogorski, Abraham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786241/ https://www.ncbi.nlm.nih.gov/pubmed/36190005 http://dx.doi.org/10.1111/dth.15747 |
Ejemplares similares
-
Prevalence of Sharing Access Credentials in Electronic Medical Records
por: Hassidim, Ayal, et al.
Publicado: (2017) -
The Complex Interplay between Nevi and Melanoma: Risk Factors and Precursors
por: Shreberk-Hassidim, Rony, et al.
Publicado: (2023) -
Acrofacial necrotic ulcers in an infant: An undiagnosed presentation
por: Sarika, Georgina-Maria, et al.
Publicado: (2022) -
Assigning Israeli medical graduates to internships
por: Bronfman, Slava, et al.
Publicado: (2015) -
Allergic Rhinitis and Asthma Among Adolescents with Psoriasis: A Population-based Cross-sectional Study
por: GALILI, Eran, et al.
Publicado: (2020)